_256_384.jpg)
Drug Approval | October 12, 2021
Covaxin for kids gets nod, final approval awaited
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
This opens up a huge market for the company’s Magnezis implants in India
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
The first clinical trial is expected to commence in early 2022 both in Europe and the US
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
Subscribe To Our Newsletter & Stay Updated
